Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

About Aimmune Therapeutics

Aimmune Therapeutics logoAimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company's Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. Its lead product, AR101, which has completed a Phase II study, is designed to treat peanut allergy. The Company's AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AIMT
  • CUSIP:
Key Metrics:
  • Previous Close: $16.57
  • 50 Day Moving Average: $14.84
  • 200 Day Moving Average: $13.61
  • 52-Week Range: $9.77 - $26.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.47
  • P/E Growth: 0.23
  • Market Cap: $672.26M
  • Outstanding Shares: 42,254,000
Profitability:
  • Return on Equity: -1,239.53%
  • Return on Assets: -28.59%
Debt:
  • Current Ratio: 29.58%
  • Quick Ratio: 29.58%
Additional Links:
Companies Related to Aimmune Therapeutics:

Analyst Ratings

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.25 (127.84% upside)

Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00View Rating Details
9/23/2016Piper Jaffray Cos.Reiterated RatingOverweight$38.00View Rating Details
9/21/2016WedbushReiterated RatingOutperform$42.00View Rating Details
8/19/2016Credit Suisse Group AGReiterated RatingBuy$35.00View Rating Details
5/16/2016Bank of America Corp.Reiterated RatingBuyView Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/10/2016Q216($0.42)($0.43)ViewN/AView Earnings Details
5/16/2016Q116($0.40)($0.37)ViewN/AView Earnings Details
3/3/2016Q415($0.35)($0.39)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)
Current Year EPS Consensus Estimate: $-1.7 EPS
Next Year EPS Consensus Estimate: $-2.13 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.28)($0.28)($0.28)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.44)($0.44)($0.44)
Q4 20161($0.46)($0.46)($0.46)
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.52)($0.52)($0.52)
Q4 20171($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aimmune Therapeutics (NASDAQ:AIMT)
Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 68.87%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2016Mary M RozenmanInsiderSell30,000$16.80$504,000.00View SEC Filing  
5/31/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell240,000$15.23$3,655,200.00View SEC Filing  
3/29/2016Longitude Capital Partners Ii,Major ShareholderBuy78,504$13.87$1,088,850.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)
DateHeadline
finance.yahoo.com logoCoverage initiated on Aimmune Therapeutics by JMP Securities (NASDAQ:AIMT)
finance.yahoo.com - September 26 at 3:24 PM
News IconAimmune Therapeutics Inc. (NASDAQ: AIMT) Rating Reiterated at Wedbush - BNB Daily (blog) (NASDAQ:AIMT)
www.baseball-news-blog.com - September 22 at 9:18 AM
businesswire.com logoAimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company ... (NASDAQ:AIMT)
www.businesswire.com - September 21 at 4:20 PM
streetinsider.com logoAimmune Therapeutics (AIMT) Completes Target Enrollment in AR101 Phase 3 PALISADE Trial (NASDAQ:AIMT)
www.streetinsider.com - September 21 at 4:20 PM
biz.yahoo.com logoAimmune Therapeutics Inc Conference Call to Discuss the AR101 Clinical Program Updates scheduled for 5:00 pm ET today (NASDAQ:AIMT)
biz.yahoo.com - September 21 at 4:20 PM
streetinsider.com logoAimmune Therapeutics (AIMT) Completes Target Enrollment in AR101 Phase 3 PALISADE Trial - StreetInsider.com (NASDAQ:AIMT)
www.streetinsider.com - September 21 at 10:07 AM
biz.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib (NASDAQ:AIMT)
biz.yahoo.com - September 21 at 10:07 AM
publicnow.com logoAimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. (NASDAQ:AIMT)
www.publicnow.com - September 21 at 10:07 AM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) - Frisco Fastball (NASDAQ:AIMT)
friscofastball.com - September 20 at 3:23 PM
News IconSell-side is Weighing in on Aimmune Therapeutics Inc (NASDAQ:AIMT) Earnings - Frisco Fastball (NASDAQ:AIMT)
friscofastball.com - September 19 at 8:09 AM
News IconAimmune Therapeutics Inc (AIMT) Stock Price Down 6.3% Following Insider Selling - DailyQuint (NASDAQ:AIMT)
dailyquint.com - September 19 at 8:09 AM
News IconWhat are Research Firms Saying About Aimmune Therapeutics Inc (NASDAQ:AIMT)? - Frisco Fastball (NASDAQ:AIMT)
friscofastball.com - September 17 at 3:23 PM
News IconEarnings Analysis & Update for Aimmune Therapeutics Inc (NASDAQ:AIMT)? - Frisco Fastball (NASDAQ:AIMT)
friscofastball.com - September 17 at 8:09 AM
News IconStock Update on Earnings & Estimates for Aimmune Therapeutics Inc (NASDAQ:AIMT) - Frisco Fastball (NASDAQ:AIMT)
friscofastball.com - September 15 at 3:21 PM
News IconAnalysts Take: Aimmune Therapeutics Inc (NASDAQ:AIMT) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:AIMT)
friscofastball.com - September 14 at 3:23 PM
capitalcube.com logoAimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:AIMT)
www.capitalcube.com - September 14 at 9:13 AM
News IconAimmune Therapeutics Inc. (NASDAQ: AIMT) Stock Upgraded at ... - BNB Daily (blog) (NASDAQ:AIMT)
www.baseball-news-blog.com - August 29 at 8:08 AM
News IconInvestment Analysts' Updated EPS Estimates for August, 26th (AIMT,... (NASDAQ:AIMT)
www.topix.com - August 27 at 8:10 AM
News IconAimmune Therapeutics Inc. (NASDAQ: AIMT) Stock Rating Reiterated at Wedbush - BNB Daily (blog) (NASDAQ:AIMT)
www.baseball-news-blog.com - August 25 at 3:23 PM
streetinsider.com logoAimmune Therapeutics (AIMT): Expecting Success In Palisades Trial - Piper Jaffray - StreetInsider.com (NASDAQ:AIMT)
www.streetinsider.com - August 23 at 8:55 AM
live-pr.com logoNewly released market study: Aimmune Therapeutics, Inc. (AIMT) - Financial and Strategic SWOT Analysis Review (NASDAQ:AIMT)
www.live-pr.com - August 22 at 8:11 AM
biz.yahoo.com logoAimmune Therapeutics Inc Call to Discuss the Publication of the DEVIL study data and potential implications for development of AR101 scheduled for 4:30 pm ET today (NASDAQ:AIMT)
biz.yahoo.com - August 22 at 8:11 AM
finance.yahoo.com logoAIMMUNE THERAPEUTICS, INC. Financials (NASDAQ:AIMT)
finance.yahoo.com - August 20 at 3:25 PM
News IconNews review of 2 biotech stocks: Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Raptor Pharmaceuticals Corp ... - The Voice Registrar (NASDAQ:AIMT)
voiceregistrar.com - August 20 at 8:22 AM
News IconActive News in Reviews- OncoMed Pharmaceuticals (OMED), Aimmune Therapeutics (AIMT), Cardinal Financial (CFNL) - Seneca Globe (NASDAQ:AIMT)
www.senecaglobe.com - August 19 at 11:49 AM
finance.yahoo.com logo8:02 am Aimmune Therapeutics will host call to discuss the results of an independent academic clinical trial demonstrating the ability of low-dose oral immunotherapy to induce unresponsiveness in peanut-allergic children (NASDAQ:AIMT)
finance.yahoo.com - August 18 at 11:48 AM
publicnow.com logoAimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children (NASDAQ:AIMT)
www.publicnow.com - August 18 at 11:48 AM
marketexclusive.com logoAimmune Therapeutics Inc (NASDAQ:AIMT) Is Bringing A 100 Year Old Treatment Into The 21st Century - Market Exclusive (NASDAQ:AIMT)
marketexclusive.com - August 16 at 3:25 PM
insidermonkey.com logoAimmune Therapeutics Inc (AIMT) Is Bringing A 100 Year Old Treatment Into The 21st Century (NASDAQ:AIMT)
www.insidermonkey.com - August 16 at 3:25 PM
marketexclusive.com logoAimmune Therapeutics Inc (NASDAQ:AIMT) Is Bringing A 100 Year Old Treatment Into The 21st Century (NASDAQ:AIMT)
marketexclusive.com - August 16 at 11:59 AM
kcregister.com logoWorth Watching Stocks: Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Pernix Therapeutics Holdings, Inc. (NASDAQ ... - KC Register (NASDAQ:AIMT)
www.kcregister.com - August 15 at 10:39 AM
News IconAimmune Announces Second Quarter 2016 Financial Results (NASDAQ:AIMT)
www.biospace.com - August 11 at 9:16 PM
sg.finance.yahoo.com logoAimmune Therapeutics reports 2Q loss (NASDAQ:AIMT)
sg.finance.yahoo.com - August 10 at 9:50 PM
publicnow.com logoAimmune Therapeutics Announces Second Quarter 2016 Financial Results (NASDAQ:AIMT)
www.publicnow.com - August 10 at 9:50 PM
finance.yahoo.com logoAimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:AIMT)
finance.yahoo.com - August 9 at 12:09 PM
News IconAimmune Therapeutics Inc Can't Burn Your Long Portfolio. Has Another Strong Session - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 22 at 8:24 PM
News IconAimmune Therapeutics Inc Gaps Up; Strong Momentum for Buyers - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 22 at 3:22 PM
News IconStock Moving Lower for the Month; Investor Update on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT)
www.engelwooddaily.com - July 21 at 3:22 PM
News IconAimmune Therapeutics Inc's Stock Is Buy After Today's Huge Increase - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 21 at 3:22 PM
News IconAimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 23.82% After Market Selling - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 19 at 3:24 PM
News IconIncreased Volatility Noted on Shares of: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT)
www.engelwooddaily.com - July 16 at 3:22 PM
News IconIncreased Volatility Noted on Shares of: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT)
www.engelwooddaily.com - July 16 at 3:22 PM
News IconHow Many Aimmune Therapeutics Inc (NASDAQ:AIMT)'s Analysts Are Bullish? - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 16 at 3:22 PM
News IconHow Many Aimmune Therapeutics Inc (NASDAQ:AIMT)'s Analysts Are Bullish? - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 16 at 3:22 PM
News IconAimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 2.16% After Market Selling - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 16 at 3:22 PM
News IconAimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 2.16% After Market Selling - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 16 at 3:22 PM
News IconShares Losing Ground for the Month; Investor Alert on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT)
www.engelwooddaily.com - July 14 at 12:18 PM
News IconEye on Stock Volatility for: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT)
www.engelwooddaily.com - July 14 at 12:18 PM
News IconAimmune Therapeutics Incorporated (NASDAQ:AIMT) Sellers Increased By 2.16% Their Shorts - Consumer Eagle (NASDAQ:AIMT)
www.consumereagle.com - July 13 at 11:28 AM
fiscalstandard.com logoAimmune Therapeutics, Inc. (NASDAQ:AIMT) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:AIMT)
www.fiscalstandard.com - July 11 at 8:11 AM

Social

Aimmune Therapeutics (NASDAQ:AIMT) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff